Josh Rappaport is a Managing Director at Stern IR. Since joining the firm in early 2017, Josh has worked with public and private biopharmaceutical companies across all stages of development. His experience spans numerous therapeutic areas, including oncology and rare disease, infectious and genetic disease, as well as CNS, autoimmune and metabolic disorders. In addition, he has positioned clients with a range of business models, from complex corporate structures and single-product stories to leading platforms for drug discovery, gene and cell therapy, etc.
Josh has advised companies on IR strategy at various stages in their lifecycle, through crossover and other private financings, reverse-mergers, IPOs and follow-ons; high-value business development and M&A transactions; restructurings and shifts in positioning; defense of shareholder activism; and major clinical data and regulatory disclosures. He enjoys partnering closely with clients to best convey their investment thesis, build credibility on the Street and accelerate their impact via the capital markets.
Before Stern IR, Josh held roles in corporate development at early-stage companies, Verificient Technologies and N&C, Inc. Previously, he supported policy priorities and other patient advocacy efforts at the Epilepsy Foundation and the National Association of Councils on Developmental Disabilities.
Josh graduated with a B.A. in Economics from the University of Maryland, where he was a College Park Scholar. Outside of work, he enjoys eating well with friends and family and is an avid basketball fan. He is based in Cambridge, MA.
